ACMT & AACT Joint Position Statement on Nalmefene Should Not Replace Naloxone as the Primary Opioid Antidote at This Time. - ACMT
The potential benefits of nalmefene over naloxone carry risk of causing harm. These benefits, if present, should be demonstrated in the clinical environment, balanced with the risks, and compared to naloxone prior to broad adoption of nalmefene.| ACMT
